{"nctId":"NCT04043806","briefTitle":"A Study Evaluating the Long-term Safety of VX-445 Combination Therapy","startDateStruct":{"date":"2019-08-09","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":458,"armGroups":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA"]}],"interventions":[{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Currently participating in study VX17-659-105 (NCT03447262)\n\nExclusion Criteria:\n\n* History of drug intolerance in study VX17-659-105 that would pose an additional risk to the participant in the opinion of the investigator\n* Current participation in an investigational drug trial (other than study VX17-659-105)\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"435","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":75,"n":457},"commonTop":["Cough","Infective pulmonary exacerbation of cystic fibrosis","Headache","Upper respiratory tract infection","Sputum increased"]}}}